Docetaxel Plus Gemcitabine or Docetaxel Plus Cisplatin in Advanced Pancreatic Carcinoma: Randomized Phase II Study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group - Concepedia

Concepedia

Publication | Open Access

Docetaxel Plus Gemcitabine or Docetaxel Plus Cisplatin in Advanced Pancreatic Carcinoma: Randomized Phase II Study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group

DOI Full Paper Access

46

Citations

26

References

2005

Year

Manfred P. Lutz, Eric Van Cutsem, Theo Wagener, Jean–Luc Van Laethem, U. Vanhoefer, J. Wils, Eric Gamelin, Claus H. Koehne, Jean Arnaud, Emmanuel Mitry,

Journal of Clinical Oncology

Abstract

Both regimens are well tolerated and show activity in advanced pancreatic carcinoma. The safety profile and survival analyses favor docetaxel plus gemcitabine for further evaluation.

References

	Year	Citations

Page 1